IL6 and coronary artery disorder: By contrast, genetic associations with CHD risk for variants in the IL6R gene region (61, 63) and the IL1RN gene region (62) provide evidence that the interleukin-6 and interleukin-1 pathways, respectively, are implicated in CHD etiology and that these pathways are worthwhile therapeutic targets [as has now been demonstrated clinically for interleukin-1 (81)].